FINWIRES · TerminalLIVE
FINWIRES

Telix Says Marketing Authorization Application for Glioma Imaging Candidate Accepted for Review in Europe; Shares Up 3%

By

-- Telix Pharmaceuticals (ASX:TLX) said Friday its marketing authorization application filed in Europe for TLX101-Px, its glioma imaging candidate, has been validated and accepted for review, moving into a 210-day active assessment phase.

In a statement, the company said it is seeking a broad clinical label, reflective of current clinical practice guidelines, with national marketing authorizations expected to follow shortly after a positive outcome at day 210.

The company said it aims to expand patient access to advanced imaging that can distinguish progressive or recurrent glioma from treatment-related changes in both adults and children, with potential for additional future indications.

TLX101-Px is also being developed as a patient selection and response assessment tool for Telix's glioblastoma therapy candidate TLX101-Tx, which has been granted orphan drug designation in Europe and the US, per the statement.

The phase 3 IPAX-BrIGHT trial of TLX101-Tx in patients with recurrent glioblastoma has started patient dosing internationally and is launching in multiple European countries, the company said.

Telix Pharmaceuticals' shares were up 3% in recent Friday trade.

Related Articles

Asia

Cambricon's Profit Soars 185% in Q1, Revenue Jumps 160% on AI Boom

Cambricon Technologies (SHA:688256) reported a 185% jump in attributable net profit in the first quarter of 2026 to 1.01 billion yuan from 355.5 million yuan.Earnings per share nearly tripled to 2.38 yuan from 0.85 yuan, according to a Shanghai Stock Exchange filing on Thursday.The Chinese semiconductor company's revenue surged 160% to 2.88 billion yuan from 1.11 billion yuan a year prior, which it attributed to the continued surge in computing power demand from the artificial intelligence industry.

$SHA:688256
Asia

Update: ANZ Group Holdings Posts Higher Fiscal H1 Cash Earnings, Operating Income

(Updates to add stock movement in the last paragraph)ANZ Group Holdings (ASX:ANZ, NZE:ANZ) reported Friday fiscal first-half cash earnings of AU$1.242 per share, up from AU$1.17 a year earlier.Analysts polled by FactSet expected earnings of AU$1.23.Operating income for the six months ended March 31 was AU$11.2 billion, compared with about AU$11 billion a year earlier. Analysts surveyed by FactSet expected AU$11.39 billion.The board declared an interim dividend of AU$0.83 per share, unchanged from the prior corresponding period, payable July 1 to shareholders on record as of May 12.The company's shares on the Australian and New Zealand bourses fell around 1% and 2%, respectively, in recent Friday trade.

$ASX:ANZ$NZE:ANZ
Asia

Larvotto Resources Shares Up As New South Wales Antimony-Gold Project Plant Refurbishment Works Progress

Larvotto Resources' (ASX:LRV) shares rose 1% in recent trading on Friday after it said late on Thursday that plant refurbishment works at the Hillgrove antimony-gold project in New South Wales were advancing on schedule and on budget, with commissioning expected in the middle of the year.Equipment from the processing plant, including tanks, pumps, and hydraulic drives, was removed, disassembled, and dispatched for refurbishment to various service providers. Primary and secondary crusher refurbishment is nearing completion.Induced polarization surveys were completed at the project, with results used to generate new drill targets.

$ASX:LRV